CO2020008561A2 - Dosificación subcutánea de anticuerpos anti-cd38 - Google Patents

Dosificación subcutánea de anticuerpos anti-cd38

Info

Publication number
CO2020008561A2
CO2020008561A2 CONC2020/0008561A CO2020008561A CO2020008561A2 CO 2020008561 A2 CO2020008561 A2 CO 2020008561A2 CO 2020008561 A CO2020008561 A CO 2020008561A CO 2020008561 A2 CO2020008561 A2 CO 2020008561A2
Authority
CO
Colombia
Prior art keywords
antibodies
subcutaneous dosage
disclosed
methods
cancers
Prior art date
Application number
CONC2020/0008561A
Other languages
English (en)
Inventor
Martin Dahl
Eric Fedyk
Robert Evans
Lin Zhao
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CO2020008561A2 publication Critical patent/CO2020008561A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se divulgan métodos para administrar anticuerpos anti-CD38 aislados a dosis bajas por vía subcutánea. Los métodos proporcionan un tratamiento eficaz para enfermedades autoinmunitarias y tipos de cáncer, incluso enfermedades hematológicas. También se divulgan formas de dosis unitaria para los anticuerpos anti-CD38.
CONC2020/0008561A 2018-01-12 2020-07-13 Dosificación subcutánea de anticuerpos anti-cd38 CO2020008561A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862617146P 2018-01-12 2018-01-12
PCT/US2019/013547 WO2019140410A1 (en) 2018-01-12 2019-01-14 Subcutaneous dosing of anti-cd38 antibodies

Publications (1)

Publication Number Publication Date
CO2020008561A2 true CO2020008561A2 (es) 2020-10-30

Family

ID=65529766

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0008561A CO2020008561A2 (es) 2018-01-12 2020-07-13 Dosificación subcutánea de anticuerpos anti-cd38

Country Status (11)

Country Link
US (1) US20210388103A1 (es)
EP (1) EP3737702A1 (es)
JP (2) JP2021510737A (es)
KR (1) KR20210006321A (es)
CN (1) CN112739715A (es)
AU (1) AU2019208102A1 (es)
BR (1) BR112020014052A2 (es)
CA (1) CA3088199A1 (es)
CO (1) CO2020008561A2 (es)
MX (1) MX2020007429A (es)
WO (1) WO2019140410A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837242A (en) 1992-12-04 1998-11-17 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2649037T3 (es) 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US7497862B2 (en) 2001-08-03 2009-03-03 Tyco Healthcare Group Lp Tissue marking apparatus and method
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8658773B2 (en) * 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2799451A1 (en) 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
US20170121417A1 (en) * 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses

Also Published As

Publication number Publication date
CN112739715A (zh) 2021-04-30
WO2019140410A1 (en) 2019-07-18
JP2024023247A (ja) 2024-02-21
JP2021510737A (ja) 2021-04-30
BR112020014052A2 (pt) 2020-12-08
RU2020126723A3 (es) 2022-02-14
AU2019208102A1 (en) 2020-07-02
US20210388103A1 (en) 2021-12-16
CA3088199A1 (en) 2019-07-18
KR20210006321A (ko) 2021-01-18
MX2020007429A (es) 2020-10-15
EP3737702A1 (en) 2020-11-18
RU2020126723A (ru) 2022-02-14

Similar Documents

Publication Publication Date Title
CO2020013252A2 (es) Dosificación subcutánea de anticuerpos anti-cd38
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
EA201690905A1 (ru) Специфические антитела против cd38 для лечения злокачественных новообразований у человека
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201892284A1 (ru) Комбинация антитела против cd20, селективного ингибитора pi3-киназы-дельта и ингибитора btk для лечения b-клеточных пролиферативных расстройств
CO2017008395A2 (es) Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol
CO2020008561A2 (es) Dosificación subcutánea de anticuerpos anti-cd38
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
EA201792209A1 (ru) Схема введения пропущенных доз инъекционных сложных эфиров палиперидона длительного действия
MX2020001727A (es) Terapia de combinacion.
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
CO2022004902A2 (es) Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab
MX2023008849A (es) Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico.
EA201990370A1 (ru) Терапия рака, связанная с crebbp
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2020001856A (es) Terapia de combinacion para tratar el cancer con administracion intravenosa de un virus vaccinia ankara modificado (mva) recombinante y un anticuerpo.
MX2021010313A (es) Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA202091743A1 (ru) Вакцинация дендритными клетками параллельно с химиотерапией
EA201992852A1 (ru) Схема дозирования тезетаксела и капецитабина
CO2022004947A2 (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente
MX2020004074A (es) Producto de combinacion para el tratamiento de cancer.
PH12016501347A1 (en) Filters for infusion sets